1 true: An acyclic, neutrally charged silanone
at last!
2 At last a polynomial retrieval algorithm is introduced.
3 At last,
a molecular classification of HCC based on geno
4 At last,
a new web query interface has been added to miR
5 At last,
all the major emitters of greenhouse gases (GHG
6 The median-follow-up for patients alive
at last assessment was 11.7 months.
7 rom 3 to 17 years at onset and 5 to 57 years
at last assessment.
8 ith a progression-free survival of 29 months
at last assessment.
9 onia decreased from 20.9% at 1 year to 16.2%
at last assessment; no patient maintained a fully indepe
10 there is evidence of fibrosis on ultrasound
at last available follow up.
11 Visual acuity
at last available follow-up correlated with surgical suc
12 e at 3 months of follow-up and globe salvage
at last available follow-up in eyes with filtering-assoc
13 Rate of globe salvage was 100%
at last available follow-up.
14 At last,
based on the amino acid content enriched in cer
15 st that such a theoretical understanding may
at last be emerging, and trace its development from hist
16 rtant catalysis-relevant reaction steps have
at last been demonstrated for gold, like migratory inser
17 ve treatments for patients with SR-aGVHD has
at last begun.
18 analyses were restricted to women whose age
at last birth (ALB) was >= 30 years, the age when fertil
19 ial cancer risk declined with increasing age
at last birth (P(trend) < 0.0001).
20 pooled odds ratio per 5-year increase in age
at last birth was 0.87 (95% confidence interval: 0.85, 0
21 In this large pooled analysis, late age
at last birth was independently associated with a reduce
22 ally infected; mean [standard deviation] age
at last chart review, 20.9 [5.4] years), psychiatric and
23 ber of children, age at first child, and age
at last child) and overall [longevity, body mass index (
24 , rs17293443-C was associated with later age
at last child.
25 or probable CBD at presentation, 13/19 (68%)
at last clinical assessment.
26 Mean follow-up
at last clinical visit was 66 +/- 46 months.
27 remission (Rem1) and 1- and 3-year remission
at last contact (Rem1/3-LC).
28 ients were censored at death, at 56 days, or
at last contact if lost to follow-up.
29 actors predicting against complete remission
at last contact included onset age>/=10 years (hazard ra
30 atic carriers were right censored at the age
at last contact or age at death.
31 y, and 25,483 controls whose age at death or
at last contact was at or below the age corresponding to
32 story of seizures were in terminal remission
at last contact, only 74 (12% of those with a history of
33 taining regimen and surgery and remain alive
at last contact, whereas only one (6%) of 18 patients tr
34 ores of 90 or 100, and in 17%, a score of 80
at last contact.
35 ission; 311 (60%) were in complete remission
at last contact.
36 At last count almost 30 clinical trials targeting CD19 w
37 At last count, nearly 5000 halogenated natural products
38 re-late life (age of onset <55 years and age
at last diagnosis <55 years), and 36.9% for no PTSD (P <
39 fter adjusting for covariates (VSD site, age
at last dose, sex, and calendar month of the index date)
40 Finally,
at last echocardiographic follow-up, PLG-SAS demonstrate
41 forty individuals (0.23%; 59+/-18 years old
at last encounter; 33% male) had an ARVC variant (G(+)).
42 stolic dysfunction or restrictive LV filling
at last evaluation (20% vs. 9%; p = 0.038); 4) 2.4-fold
43 At last evaluation (median, 48 months after vomiting ons
44 ere collected at the time of PoPH diagnosis,
at last evaluation before LT, and within 6 months and be
45 At last evaluation, 20/27 patients (74%) had mPAP <35 mm
46 At last evaluation, 277 patients (91%) are alive at 62+/
47 At last evaluation, SNHL was prevalent in 14% of patient
48 th 91% experiencing no or only mild symptoms
at last evaluation.
49 agnosis but showed equivalent renal function
at last evaluation.
50 roving to 0.18 +/- 0.13 LogMAR (20/40-20/20)
at last examination (p = 0.004), as all the patients gai
51 5.4D) reaching -1.9 +/- 0.9 (-4.0D to -0.6D)
at last examination (p = 0.12).
52 .3D) changing to 1.1 +/- 1.0D (0.0D to 3.0D)
at last examination (p = 0.88).
53 Median duration of mTOR inhibition
at last examination was 106 months (range, 1310-3717 day
54 Visual acuity
at last examination was predicted best by visual acuity
55 Visual acuity
at last examination was stable or improved in 33% of pat
56 (age at onset, 89 years) and 2 controls (age
at last examination, 82 and 77 years).
57 At last examination, GBA carriers had worse motor sympto
58 had worse VA at presentation (P = 0.024) and
at last follow up (P = 0.011) compared with eyes that un
59 ions reaching 15.9 +/- 3.3 mmHg (10-21 mmHg)
at last follow up (p = 0.21).
60 the end of treatment (T1, P=0.14) and by 18%
at last follow up (T2, P=0.035) compared with treatment
61 se, 39 patients still had a functional graft
at last follow up and 9 (18.8%) pancreas grafts were los
62 At last follow up, ACD and CCD were wider in both groups
63 At last follow up, all 39 patients with functional pancr
64 ; similarly, more patients were disease free
at last follow-up (27% vs 62%, P < 0.0001).
65 p = 0.05); they were more likely to meet TFC
at last follow-up (82% vs. 35%, p < 0.001) and have a lo
66 The primary outcome was seizure freedom
at last follow-up (Engel class IA).
67 Modified Rankin score (mRS)
at last follow-up (mean 25.6 months) was dichotomized in
68 At last follow-up (mean, 20 months), of the entering 43
69 At last follow-up (mean, 4.6 years; range, 1-16), 28 (72
70 At last follow-up (mean, 41.8 months; range, 6.5-85.0 mo
71 Seven patients were still responding
at last follow-up (median = 20 months, range 5-67 months
72 Twenty patients required a gait aid (36%)
at last follow-up (median = 60 months, range = 10-172).
73 No graft losses occurred, and
at last follow-up (median [IQR] of 13 [12-19] mo), the m
74 All others were alive and in remission
at last follow-up (median, 14.7 months).
75 apy and were healthy or only mildly disabled
at last follow-up (median, 8 months; range, 6-84 months)
76 ity and there was a 100% graft survival rate
at last follow-up (minimum 4 months).
77 e 100% at 2-5 months postoperatively and 86%
at last follow-up (P < .0001 at both time points compare
78 angle of resolution in pseudophakic children
at last follow-up (P < .0001).
79 1.6 logarithm of minimal angle of resolution
at last follow-up (P < .001).
80 t survival rate than patients receiving IR-T
at last follow-up (P < 0.001), or started and maintained
81 After surgery, VA improved to 1.0+/-0.9
at last follow-up (P = 0.002).
82 t presentation (P = 0.02), lower final stage
at last follow-up (P = 0.05), and longer time to first l
83 t rate decreased from 78% at baseline to 58%
at last follow-up (z = -1.90, p = .058), and 21 patients
84 r incidence of biopsy-proven acute rejection
at last follow-up 11% (32/151) vs. 21.2% (10/91) among t
85 At last follow-up 13 years since the primary diagnosis,
86 treated 7 years ago, and thoracoabdominal CT
at last follow-up 3 years ago did not show any recurrenc
87 were cured immediately postoperatively, and
at last follow-up [mean = -9.4 years; range, 0.2-22 year
88 ment efficacy was measured as microbial cure
at last follow-up after treatment.
89 ing the difference between the mean gradient
at last follow-up and the gradient at discharge by the t
90 in the proportion of eyes with BCVA >=20/40
at last follow-up between Group I and Group II (33% vs 9
91 l/L) were significantly decreased (P < 0.01)
at last follow-up compared with preoperatively.
92 effect was similar or only slightly smaller
at last follow-up compared with the stopping/release tim
93 male, 77% white persons, and the median age
at last follow-up date was 11.5 years.
94 to 0.8 logMAR (0.16 DIN; range 2-0.1 logMAR)
at last follow-up examination (no statistical significan
95 At last follow-up examination, BSCVA had improved in 11
96 atients (14%) with clinical ARVD/C diagnosis
at last follow-up had an abnormal ECG or Holter monitor
97 Postoperative success
at last follow-up in the circumferential vs conventional
98 At last follow-up IOP was successfully controlled in 67%
99 t a median age of 63 months and a median age
at last follow-up of 66 months.
100 the incidence of persistence of the symptom
at last follow-up ranged from 5% to 13%.
101 ery (Expanded Disability Status Scale >= 3.0
at last follow-up reached only by 10 of 97 [10.3%] vs 66
102 sk Force Criteria (not the "Hamid criteria")
at last follow-up that was absent at enrollment.
103 (P = 0.001), and a lower excess weight loss
at last follow-up visit (P < 0.001) as independent predi
104 ial presentation was 0.36 +/- 0.29logMAR and
at last follow-up visit 0.51 +/- 0.43logMAR.
105 alyzed, and rate of strabismus and nystagmus
at last follow-up visit were calculated.
106 rcentage of IOP reduction was 23.1 +/- 14.3%
at last follow-up visit.
107 and visual acuity for the pseudophakic eyes
at last follow-up visit.
108 Median age
at last follow-up was 10 years (range, 2-25 years).
109 Death-censored graft survival
at last follow-up was 100% in the ABOi and 98% in 50 com
110 All-cause mortality
at last follow-up was 15% in the preemptive therapy vs 1
111 Median visual acuity
at last follow-up was 20/400 (range, 20/30-no light perc
112 The median AL before and
at last follow-up was 22.2 and 23.1 mm, respectively.
113 Resolution of symptom rate
at last follow-up was 64% in the elderly group versus 86
114 Spherical regression
at last follow-up was an average of +0.59 D.
115 tcomes defined as modified Rankin scale (>=3
at last follow-up was considered poor) were primary outc
116 ), the proportion of patients with LVEF <55%
at last follow-up was higher in FM versus NFM (29% versu
117 Clinic attendance
at last follow-up was poor (61.9%).
118 The mean total corneal thickness
at last follow-up was significantly thicker (509 +/- 147
119 Mean preoperative cECCs and
at last follow-up were: group 1, 2525+/-338 cells/mm(2)
120 Overall, 9 of 24 patients (37.5%) were alive
at last follow-up with a median follow-up of these survi
121 (ePOST drop >/=2 points from baseline but >1
at last follow-up).
122 At last follow-up, (1/3) of the children with active epi
123 At last follow-up, 1 patient had died, and the remaining
124 .037; median number of glaucoma medications
at last follow-up, 1.49 [IQR 0-2] vs 2.54 [IQR 1-4], P <
125 At last follow-up, 11 of 31 patients progressed and 21 o
126 wo patients required mechanical ventilation;
at last follow-up, 16 were extubated.
127 At last follow-up, 174 (94%) of 185 patients were alive
128 At last follow-up, 18.8% patients with C-TCMR had >=50%
129 rved their larynx with no sign of recurrence
at last follow-up, 22 (95%) reported normal or near norm
130 dian age at diagnosis, 7.0 years; median age
at last follow-up, 31.8 years).
131 At last follow-up, 36% ambulated with assistance (mean a
132 At last follow-up, 39 (64%) patients were only on beta-b
133 At last follow-up, 4 patients had mild or no symptoms, b
134 At last follow-up, 41 patients (80%) were alive and dise
135 At last follow-up, 48% of diabetic and 62% of nondiabeti
136 At last follow-up, 55.3% were in disease remission, 5.0%
137 At last follow-up, 6 of 19 patients (31.6%) had best-cor
138 At last follow-up, 69 patients were alive, 100 underwent
139 At last follow-up, 82.7% of MVR patients had their arrhy
140 At last follow-up, 87% of the surviving patients had no
141 At last follow-up, 92% of the quiescent CNV seemed to co
142 At last follow-up, a median of 13 months after transplan
143 episodes were recorded after treatment, and
at last follow-up, all 6 surviving patients were free of
144 At last follow-up, all 7 patients with optic neuropathy
145 es), the retina remained completely attached
at last follow-up, and 5 additional eyes remained partia
146 repaired filtering blebs remained functional
at last follow-up, and no additional medications were re
147 metastases at surgery, 13 were disease-free
at last follow-up, and none of 2 patients with tumor rec
148 All retinas were attached
at last follow-up, and visual acuity was 20/400 or bette
149 significant differences between groups, and
at last follow-up, both steep and flat keratometry readi
150 ed from 2003 to 2013 and genotyped for PEPT2
At last follow-up, carriers of the PEPT2*1*1 genotype (h
151 At last follow-up, CDVA was 0.09+/-0.10 logMAR in the tP
152 At last follow-up, eyes that returned to OR and control
153 ar and systemic findings at presentation and
at last follow-up, investigations, management details, a
154 Compared with baseline,
at last follow-up, left ventricular ejection fraction di
155 At last follow-up, mean eGFR was 50.2+/-26.1 ml/min per
156 At last follow-up, most eyes with scleritis (90.4%) had
157 At last follow-up, none of the 5 patients presenting wit
158 At last follow-up, PCG showed better median VA than GFCS
159 At last follow-up, preexisting DSA had decreased or stab
160 At last follow-up, renal function was similar between th
161 ) preoperatively to 2831 +/- 236 cells/mm(2)
at last follow-up, representing a mean endothelial cell
162 ported in 65% and 85% of eyes at 1 month and
at last follow-up, respectively.
163 At last follow-up, the circumferential cohort had better
164 At last follow-up, the left ventricular ejection fractio
165 At last follow-up, the proportion of eyes reaching a vis
166 At last follow-up, there was no death, and 3 patients re
167 At last follow-up, there were 46 (18.3%) recurrences; 2
168 At last follow-up, UDVA was 0.27+/-0.25 logMAR in the tP
169 lity was achieved in 72.7% (120/165) of eyes
at last follow-up, while 15.2% (25/165) maintained an im
170 white patients were generally in good health
at last follow-up, while two-thirds (4/6) of the nonwhit
171 range = 1-5) at onset and 1.74 (range = 0-6)
at last follow-up, with 9% having severe refractory disa
172 stence was demonstrated in 11 of 14 patients
at last follow-up, with enhanced CAR T cell expansion co
173 vision, and all were considered disease free
at last follow-up.
174 week and 1 month after treatment onset, and
at last follow-up.
175 filtration rate at 12 months postbiopsy and
at last follow-up.
176 change in 7.7%, and a worsened BCVA in 18.6%
at last follow-up.
177 ellen-equivalent visual acuity (VA), and IOP
at last follow-up.
178 Visual acuity
at last follow-up.
179 rimary end point was symptomatic improvement
at last follow-up.
180 ations to control disease, and had lower IOP
at last follow-up.
181 of ptosis were evaluated before surgery and
at last follow-up.
182 Seventeen of 21 tumors (81%) were flat
at last follow-up.
183 (41.4%), moderate (18.6%), or severe (6.7%)
at last follow-up.
184 e 85 women included, 62 were free of disease
at last follow-up.
185 (BSCVA) at presentation was 20/46 and 20/48
at last follow-up.
186 ) achieved visual acuity of 20/200 or better
at last follow-up.
187 a partial response, and 3 had stable disease
at last follow-up.
188 1.34 logMAR (0.30 logMAR - light perception)
at last follow-up.
189 ts having no evidence of progressive disease
at last follow-up.
190 dren recovered without ongoing complications
at last follow-up.
191 treatment; duration of follow-up, and status
at last follow-up.
192 deviations less than 10 prism diopters (PD)
at last follow-up.
193 easures included amount of AHP and deviation
at last follow-up.
194 t least 35 years old (range, 35 to 62 years)
at last follow-up.
195 worse than 20/100 in 75% (9/12) of patients
at last follow-up.
196 Forty-two of 48 TMA leads remain active
at last follow-up.
197 ed pre-ART in 20/29 and in 8/30 participants
at last follow-up.
198 percent were on no antiglaucoma medications
at last follow-up.
199 ssment Tool, and eight had ongoing responses
at last follow-up.
200 ad ongoing viremia without clinical symptoms
at last follow-up.
201 nt for remote seizure within prior 6 months)
at last follow-up.
202 ents had recurrence or loss of visual acuity
at last follow-up.
203 ents (14%), but was <5/200 in 34 of 49 (69%)
at last follow-up.
204 3-week median duration or remission censored
at last follow-up.
205 splant, and 73 were alive without transplant
at last follow-up.
206 P therapy for a median duration of 34 months
at last follow-up.
207 ith more than 1 year follow-up and 1.4 mg/dL
at last follow-up.
208 myelination and multiple sclerosis diagnosis
at last follow-up.
209 Death-censored graft survival was 100%
at last follow-up.
210 Seventeen patients are still alive
at last follow-up.
211 at the time of withdrawal from the study or
at last follow-up.
212 d patients, 204 (21.3%) were recurrence-free
at last follow-up.
213 subsequently decreased by 18, to 56 (20/80),
at last follow-up.
214 f logMAR 1.5 at admission, and of logMAR 0.6
at last follow-up.
215 d not impact functional outcome or mortality
at last follow-up.
216 oup at postoperative months 1, 3, and 12 and
at last follow-up.
217 val rates after DMEK ranged from 92% to 100%
at last follow-up.
218 ents with early-onset ES (median [range] age
at last follow-up: 16.3 years ([1.2-41.0 years]) initiat
219 al Project birth cohort (mean age = 37 years
at last follow-up; n = 2,097; 1959-2001).
220 arctions, and less frequently needed therapy
at last followup.
221 Serial crystallography
at last generation X-ray synchrotron sources and free el
222 nd of increased HIV knowledge and condom use
at last intercourse among women.
223 comprehensive HIV knowledge, and condom use
at last intercourse.
224 significantly increased reported condom use
at last intercourse.
225 At last,
it will help users hypothesize new gene functio
226 Mortality due to coccidioidomycosis
at last known follow up was significantly different acro
227 Only first and last name and address
at last-
known residence are required to access the resid
228 essing of graphene and carbon nanotubes have
at last led to the continuous production of high-quality
229 e at menarche, current menstrual status, age
at last menstruation, and menopausal aetiology) informat
230 At last,
network analysis was conducted to identify most
231 At last,
no significant differences were observed betwee
232 At last observation (12-33 weeks), six patients were res
233 nd 50% of Turkish children were malnourished
at last observation (P < 0.005).
234 After adjusting for age
at last observation, this effect was not significant in
235 x, site, history of febrile seizure, and age
at last observation.
236 nce bone lead measures and who had completed
at last one Mental Health Index 5-item scale (MHI-5) and
237 Patient ages ranged from 2 to 27 years
at last ophthalmic visit, and follow-up ranged from 0 to
238 Estimated gestational age
at last P. falciparum infection, but not P. vivax infect
239 Clinical status
at last pediatric clinic visit prior to transfer was des
240 At last pediatric follow-up, median age was 17.4 years [
241 We argue that recent advances are
at last pinpointing individual enzyme and transporter ge
242 At last postoperative follow-up visit, UDVA improved to
243 At last postoperative follow-up, the mean IOP decreased
244 Best-corrected VAs at first and
at last presentations were 2.2 and 0.0625 logarithm of t
245 At last,
proximity between two conserved amino acids fro
246 ement of kidney function as assessed by eGFR
at last recorded follow-up compared with eGFR at the tim
247 in this case series, with a mean (range) age
at last review of 37.1 (16-70) years.
248 Of the 12 patients (6 males; mean age
at last review, 16 years [range, 2-38 years]), all had h
249 D surgery, and 8.3% had silicone oil in situ
at last review.
250 es and 1 of unrelated causes; 2 remain alive
at last review.
251 Mean reported gel use
at last sex act was 89% (95% CI 86-91).
252 Self-reported condom use
at last sex with a male partner increased from 58% in 20
253 ndependent predictor of increased condom use
at last sex with a male partner over time (adjusted odds
254 R] = 0.67; 95% CI, 0.48-0.92) and condom use
at last sexual intercourse (AOR = 0.75; 95% CI, 0.57-0.9
255 Contraceptive method
at last sexual intercourse was assessed by 1 item-respon
256 item asked whether respondents used a condom
at last sexual intercourse.
257 At last,
small single centre studies and the use of drug
258 Median age
at last surgery for the entire population was 60 years (
259 e of 24 months (median intra-patient changes
at last TE examination relative to baseline: -0.2 kPa, p
260 At last,
the black rice pigment sensitized TiO2 thin fil
261 At last,
the fracture connectivity is determined through
262 At last,
the method is further improved to give a consis
263 At last,
the primary transcriptome landscape of the beta
264 At last,
the protein-protein interaction between Dlx3 an
265 At last,
the Review offers an outlook for commercializat
266 At last,
this study also allows an accurate structural d
267 At last,
Ultrasound Doppler velocimeter measured result
268 er saturations reduced the postmenstrual age
at last use of oxygen therapy (adjusted mean difference,
269 At last,
using these optimized vectors in the context of
270 0%) maintained their best-ever visual acuity
at last visit (mean follow-up period was 37.8 months).
271 ved for ECD values (1741+/-274.5 cells/mm(2)
at last visit before rejection vs. 1356+/-380.3 cells/mm
272 f resolution [logMAR]; CCT, 554.1+/-39.1 mum
at last visit before rejection vs. BSCVA, 0.21+/-0.15 lo
273 ion criteria were comparison at baseline and
at last visit of PET and of cardiovascular and cerebral
274 as a mixed effects Cox regression, with age
at last visit to the clinic or age at cancer diagnosis a
275 (range; 5 months-14 years) and the mean age
at last visit was 11.3 +/- 6.5 years.
276 tudy; median (interquartile range [IQR]) age
at last visit was 25 (12-38) months.
277 The mean astigmatism
at last visit was 4.04 +/- 2.21 diopters.
278 BSCVA
at last visit was 7/10 or better in 6 eyes, 4/10 in 1 ey
279 Graft survival rate
at last visit was 90% for Group I and 88% for Group II.
280 Clinical diagnosis
at last visit was MSA for 28 cases.
281 al OFNF (23 male, 27 female, aged 4-48 years
at last visit) and 5 patients with bilateral OFNF (2 mal
282 on), use of TTT, and tumor-foveola distance (
at last visit) were found to be significant risk factors
283 At last visit, 6 of 27 (22%) patients had nystagmus and
284 At last visit, after a single surgery, qualified success
285 At last visit, BCVA was better than 20/50 in 131 eyes (5
286 At last visit, eyes with follow-up showed tumor regressi
287 lensectomy, date of last visit, lens status
at last visit, subsequent retinal surgeries, and retinal
288 nal surgeries, and retinal attachment status
at last visit.
289 dictors (P < 0.05) for losing 1 line or more
at last visit.
290 if performed), and retinal attachment status
at last visit.
291 fined by a modified Rankin Scale score </= 2
at last visit; 84% vs 39%; P < .001) with fewer relapses
292 Measures: VA improvement at 12-18 months and
at last visits.
293 At last we discuss how the formation of magnetite-based
294 At last,
we also outline some of our future plans for th
295 At last,
we apply this method to some real-world network
296 At last,
we briefly outline the allosteric regulation of
297 At last,
we demonstrate the utility of these tools by ex
298 At last,
we have confirmed that hypothyroid environment
299 At last,
we outline key statistics on the current data c
300 At last,
we propose an effective strategy to constrain t